Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article
link : Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article

Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article

Expert Rev Gastroenterol Hepatol. 2017 Jul 4. doi: 10.1080/17474124.2017.1351295.
[Epub ahead of print]

Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C
Rebecca Voaklander & Ira M Jacobson

Received 19 Apr 2017, Accepted 03 Jul 2017, Accepted author version posted online: 04 Jul 2017

Full Text Article
Download PDF

Abstract

Introduction

The advent of direct-acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infection has dramatically increased rates of cure. However, there remain difficult-to-treat populations, including patients with genotype 3 infection and cirrhosis, and limited salvage treatment options for those that have failed first-line DAA therapy.

Areas covered

This is a review of the preclinical and clinical development of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), an interferon-free, oral, once daily, pangenotypic treatment for chronic HCV infection. All relevant literature from 2015 through June of 2017 is included.

Expert commentary

Voxilaprevir, a second-generation HCV protease inhibitor, in combination with the already approved combination of sofosbuvir and velpatasvir, was evaluated in the POLARIS trials and found to be a safe and effective regimen. Patients with prior DAA treatment failure, genotype 3, cirrhosis and/or unfavorable resistance profiles all achieved cure rates of 96% or greater. The most distinctive role for this potent regimen may prove to be as a salvage regimen for patients who have failed previous DAA therapy.

Full Text Article
PDF link provided by Henry E. Chang via Twitter.
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading full text articles about the treatment and management of hepatitis C.

Thus articles Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article

that is all articles Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article the link address https://newsaninpiration.blogspot.com/2017/07/sofosbuvir-velpatasvir-and-voxilaprevir.html

Tweet

Subscribe to receive free email updates: